Preexisting MEK1 Exon 3 Mutations in (V600E/K)BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

BRAF inhibitors (BRAFi) induce antitumor responses in nearly 60% of patients with advanced (V600E/K)BRAF melanomas. Somatic activating MEK1 mutations are thought to be rare in melanomas, but their potential concurrence with (V600E/K)BRAF may be selected for by BRAFi. We sequenced MEK1/2 exon 3 in me...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Shi, Hubing, Moriceau, Gatien, Kong, Xiangju, Koya, Richard C., Nazarian, Ramin, Pupo, Gulietta M., Bacchiocchi, Antonella, Dahlman, Kimberly B., Chmielowski, Bartosz, Sosman, Jeffrey A., Halaban, Ruth, Kefford, Richard F., Long, Georgina V., Ribas, Antoni, Lo, Roger S.
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3594852/
https://ncbi.nlm.nih.gov/pubmed/22588879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0022
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars